Bristol Myers Squibb Updates Phase 3 YELLOWSTONE Trial Progress: Oral Zeposia (Ozanimod) Evaluation in Moderate to Severe Active Crohn’s Disease Patients

Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program, which assesses Zeposia (ozanimod) in adult patients dealing with moderate…

Read MoreBristol Myers Squibb Updates Phase 3 YELLOWSTONE Trial Progress: Oral Zeposia (Ozanimod) Evaluation in Moderate to Severe Active Crohn’s Disease Patients

Bristol Myers Squibb Broadens Health Equity Grant Programs for Enhanced Health Results

Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations: Brazil, India, Thailand, and the United Kingdom. These new grants…

Read MoreBristol Myers Squibb Broadens Health Equity Grant Programs for Enhanced Health Results

Bristol Myers Squibb Presents New Cardiovascular Findings at 2024 ACC Conference, Strengthening Evidence Base

Bristol Myers Squibb (NYSE: BMY) announced today the unveiling of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, in Atlanta, Georgia. Roland Chen, MD, Senior Vice President and Head of…

Read MoreBristol Myers Squibb Presents New Cardiovascular Findings at 2024 ACC Conference, Strengthening Evidence Base

AbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused on developing novel oral therapeutics for patients with autoimmune diseases.…

Read MoreAbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions

Novo Nordisk’s Acquisition of Cardior Pharmaceuticals: Enhancing Cardiovascular Disease Pipeline

Novo Nordisk and Cardior Pharmaceuticals have announced a significant acquisition deal, with Novo Nordisk set to acquire Cardior for up to 1.025 billion Euros. This includes an upfront payment along with additional payments contingent upon the achievement of specific developmental…

Read MoreNovo Nordisk’s Acquisition of Cardior Pharmaceuticals: Enhancing Cardiovascular Disease Pipeline

Awiqli®: European Authorities Recommend Approval for Weekly Basal Insulin Icodec in Diabetes Treatment

Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded name for once-weekly basal insulin icodec) for the treatment of…

Read MoreAwiqli®: European Authorities Recommend Approval for Weekly Basal Insulin Icodec in Diabetes Treatment

Comprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com

The “Global Covid-19 Diagnostic Market Forecast by Technology, Product, Channel and Country with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Amidst signs of the pandemic easing, Covid-19 continues to reshape markets, especially in the realm of respiratory diagnostics, where a…

Read MoreComprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com